[Results of the sequential use of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia].

Abstract

AIM:

To study the efficacy and safety of mexidol's intravenous injections (500 mg once a day) for 14 days, followed by oral administration of mexidol FORTE 250 at a dose of 250 mg (1 tablet) 3 times a day for 60 days, in treatment of chronic cerebral ischemia (CCI) in patients with hypertension and atherosclerosis of the brachiocephalic arteries.

MATERIAL AND METHODS:

The observation program included 60 patients with an established diagnosis of CCI confirmed by neuroimaging methods. Patients of the main group (n=26) received mexidol along with basic therapy, patients of the comparison group (n=26) received only basic therapy.

RESULTS AND CONCLUSION:

The results of the experience show the high efficacy and safety of sequential therapy (parenteral therapy followed by tablets of mexidol FORTE 250). The treatment improves emotional and cognitive status, decreases static-motor disorders and severity of subjective neurological symptoms. High adherence of patients to the therapy is shown.

• Authors: Yu V Abramenko
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 120 Issue 3. Vyp. 2 Pg. 59-64 ( 2020) ISSN: 1997-7298 [Print] Russia (Federation)
• Vernacular Title: Rezul'taty posledovatel'nogo primeneniia preparatov Meksidol i Meksidol Forte 250 u bol'nykh s khronicheskoĭ ishemieĭ golovnogo mozga.
• PMID: 32307432 (Publication Type: Journal Article, Observational Study)

Chemical References

• Picolines
• emoxypine succinate

Topics

• Brain Ischemia (drug therapy, physiopathology, psychology)
• Chronic Disease (therapy)
• Humans
• Neuroimaging
• Picolines (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome